Skip to main content
. 2020 Jun 2;92(10):1922–1931. doi: 10.1002/jmv.25893

Table 1.

Demographic and clinical manifestations of COVID‐19 pneumonia patients

All patients (n = 184) Symptomatic treatment (n = 17) Arbidol (n = 30) Lopinavir/ritonavir (n = 27) Arbidol+  lopinavir/ritonavir (n = 25) Interferon (n = 41) Interferon + lopinavir/ritonavir (n = 21) Interferon + darunavir (n = 23) P value
Age,y 48.7 ± 15.6 49.0 ± 14.3 47.0 ± 15.6 49.4 ± 14.8 54.0 ± 15.4 46.2 ± 18.1 47.1 ± 15.3 50.3 ± 13.2 .578 a
Sex .564 b
Male 99 (54%) 8 (47%) 18 (60%) 15 (56%) 16 (64%) 17 (42%) 11 (52%) 14 (61%)
Female 85 (46%) 9 (53%) 12 (40%) 12 (44%) 9 (36%) 24 (59%) 10 (48%) 9 (39%)
Duration, d 4.0 (3.0‐7.0) 4.0 (2.0‐6.0) 4.0 (3.0‐6.5) 5.0 (3.0‐8.0) 3.0 (2.0‐6.0) 5.0 (3.0‐8.0) 6.0 (3.0‐9.0) 5.0 (2.0‐7.0) .245 c
Clinical manifestations
Fever 144 (78%) 14 (82%) 20 (67%) 23 (85%) 23 (92%) 30 (73%) 18 (86%) 16 (70%) .277 b
Cough 83 (45%) 4 (24%) 15 (50%) 14 (52%) 12(48%) 21 (51%) 5 (24%) 12 (52%) .174 b
Little phlegm 47 (26%) 2 (12%) 6 (20%) 9 (33%) 5 (20%) 14 (34%) 3 (14%) 8 (35%) .254 b
Stuffy and runny nose 13 (7%) 1 (6%) 1 (3%) 1 (4%) 0 (0%) 7 (17%) 1 (5%) 2 (9%) .201 d
Chest congestion 12 (6%) 1 (6%) 1 (3%) 3 (11%) 1 (4%) 1 (2%) 4 (19%) 1 (4%) .250 d
Headache 22 (12%) 1 (6%) 5 (17%) 2 (7%) 1 (4%) 6 (15%) 4 (19%) 3 (13%) .624 d
Myalgia or fatigue 55 (30%) 5 (29%) 12 (40%) 5 (19%) 9 (36%) 12 (29%) 6 (29%) 6 (26%) .709 b

Note: Data are mean ± SD, n (%), and median (IQR).

Abbreviations: ANOVA, analysis of variance; COVID‐19, coronavirus disease 2019; duration, duration from illness onset to admission; IQR, interquartile range.

a

P value comparing groups is from ANOVA.

b

P value comparing groups is from χ 2 tests.

c

P value comparing groups is from the Kruskal‐Wallis test.

d

P value comparing groups is from Fisher's exact test.